Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07537413 · ClinicalTrials.gov registry record · Phase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 4
- Development phase
- 430
- Enrollment target
NCT07537413: Clinical Trial Phase 4 study, sponsored by University of Maryland, Baltimore.
NCT07537413 is a Phase 4 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 430 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07537413, a Phase 4 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 430 participants
- Enrollment target
Study Summary
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Primary Outcome
Defined by discharge from the hospital or antibiotic treatment for \< 8 days without any of the following: requirement for antibiotic escalation, admission to an intensive care unit, mechanical or noninvasive ventilation, readmission within 30 days, or mortality within 30 days
Interventions
- DRUG Ceftriaxone 1 gram daily
- DRUG Ceftriaxone 2 grams daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 4 |
What is known before NCT07537413 opens enrollment
NCT07537413 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Ceftriaxone 1 gram daily is the first listed.
NCT07537413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07537413 about?
NCT07537413 is a clinical study titled "Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia". Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the...
What is the current status of trial NCT07537413?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 430 participants. The study started on 2026-09-01. Estimated completion is 2028-02-28.
What interventions are being tested in trial NCT07537413?
The interventions under investigation include: Ceftriaxone 1 gram daily (DRUG), Ceftriaxone 2 grams daily (DRUG).
Who is sponsoring clinical trial NCT07537413?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07537413's enrollment target sits among peer trials
430 194th of 2000 higher than 1,806 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI